New Document top_band
 
Business Standard

Dr Reddy's Lab rises 2.3%

Read more on:    Nordic Bioscience | Dr Reddys Lab
Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

FIIs may still buy around $135 billion of stocks in Nifty: UBS

Says markets may consolidate after the run up but significant downside may be limited

PSU divestment hopefuls outperform markets

Stocks like BEML have risen as much as 300% in the past one year

Palm oil up 0.4% on rising demand

Oil for delivery in July edged up by 0.26%

Silver up 0.5% in futures trade

Metal for delivery in far-month December traded higher by 0.29%

Mentha oil falls 0.58% on profit-booking

Oil for delivery in the August traded lower by 0.48%

Back to Top